ライフサイエンスコーパス: person

1 artile 1-quartile 3]: 78.3 [66.3-83.0] hours/person).

2 idence from 2008 to 2019 by time, place, and person.

3 o ingested gluten in genetically susceptible persons.

4 rates between untreated and PEG/RBV-treated persons.

5 rescriptions (96 DOAC, 140 warfarin) for 206 persons.

6 -born PLWH was low compared to non-U.S. born persons.

7 s prioritized testing for specific groups of persons.

8 ikely to receive a positive result than were persons 10 years of age or older, with percentages of 6.

9 Of the 11 066 tested persons, 115 (1%) were hospitalized adults investigated

10 conferred 95% protection against Covid-19 in persons 16 years of age or older.

11 nce interval [CI] 19.6-21.6) among untreated persons, 19.8 (95% CI 18.3-21.4) among those treated wit

12 states encompassing approximately 17 million persons (5% of the national population).

13 rted surveys, we estimated that 24.8 million persons (7.7%) had presenting VI or blindness.

14 Of the positive persons, 7292 were hospitalized directly upon presentati

15 .1 trillion in 2016 (17.9% of GDP; $9655 per person); 85.2% of that spending was included in this stu

16 used acute and chronic HCV infections among persons aged <=40 years as a proxy measure of IDU.

17 2016), and annual percentage change (APC) in persons aged 20 to 29, 30 to 39, 40 to 49, and 50 to 54

18 .25 (95% confidence interval: 1.18, 1.33) in persons aged 30-49 years at enrollment to 1.13 (95% conf

19 In persons aged 40 to 49 years, 3-year average annual IRs i

20 cial cohesion with depressive symptoms among persons aged 50 years or more in 16 different countries.

21 0 U.S. population includes 5.04 million more persons aged 65 years and older than the average populat

22 3006 persons aged 75 years or older who were hospitalized wit

23 3 of the leading causes of death among young persons (aged 10-24 years): unintentional injuries inclu

24 on was 10.3% and was significantly higher in persons ages 15 to 24 years than in persons ages 35 to 3

25 igher in persons ages 15 to 24 years than in persons ages 35 to 39 years (for females, 19.8% versus 4

26 nsitivity for the subjective perception of a person and how well they treat you during choice.

27 e nature of the analysis, the use of both in-person and phone survey data for international migrants,

28 Measures of fluorosis severity at the person and tooth level were calculated: second highest F

29 needed on the effects of screening high-risk persons and to identify quality measures for diagnosis,

30 7%), serving smaller populations (mean 1,102 persons), and serving Hispanic communities (38.3%).

31 or older, including pregnant and postpartum persons, and adolescents aged 12 to 17 years in primary

32 et share, county-level procedures per 10 000 persons, and patient-level postoperative outcomes.

33 splant (KT) outcomes for HIV-infected (HIV+) persons are excellent, yet acute rejection (AR) is commo

34 Unvaccinated or previously uninfected persons are susceptible to HAV infection, yet the suscep

35 a range of clinical preventive services for persons at average risk for disease.

36 o compensatory neurofunctional mechanisms in persons at familial risk for schizophrenia.

37 tegies and the accuracy of tools to identify persons at increased risk.

38 ude recommendations for screening for HCC in persons at risk, treatment with antivirals, and an emerg

39 to a multi-category stimulus (e.g., a whole person) based on the response to its component stimuli p

40 LTBI prevalence estimates were lowest for persons born in Colombia, Malaysia, and Thailand, rangin

41 Persons born in regions with a prevalence of HBV infecti

42 mate rather than inanimate (we can caution a person, but not an object).

43 This letter is not about a single person, but the Black academic's experience of race insi

44 In some persons C-reactive protein clearly dropped only after th

45 er care that moves beyond the traditional in-person care model to real-time, dynamic, and technology-

46 Using an efficient child- and young person-centered approach, we developed 2 robust, age-app

47 n was video recorded before the first SEE in-person coaching session, which included teaching eye dro

48 at enrolled chronic genotype 1a HCV-infected persons coinfected with suppressed HIV: 5 of 6 treatment

49 In-person communication with patients hospitalized with COV

50 For example, can a person compute a function in his or her head so that an

51 COVID-19 pandemic has brought traditional in-person conferences to a halt for the foreseeable future,

52 ask that required understanding what another person could see or how they see it, respectively.

53 At the third and final in-person counseling session 6 months later, eye drop admin

54 (1) automated medication reminders, (2) 3 in-person counseling sessions with a glaucoma coach who had

55 Using representative samples, we find that person-country and person-region value congruence predic

56 ially, however, value type moderates whether person-country fit is positively or negatively associate

57 The first database is a conventional on-the-person database called MIT-BIH, and the second is one le

58 he local strategy causes significantly fewer person-days of closure, even under high intercounty trav

59 Specifically, per 10 million person-days, each 1-mug/m3 increase in long- and short-t

60 Information on the profession of the person delivering the intervention was often not availab

61 ns is a major challenge in ensuring that all persons diagnosed with drug-resistant TB are started on

62 ion, (B) factors that relate to the specific person doing the analysis, which include past experience

63 Amid the impromptu upheaval of in-person education across the world, this article aims to

64 egression models were used to compare within-person effects, controlling for time-varying confounders

65 = 57 [91.9%]), temperature screening of all persons entering clinical space (n = 34 [54.84%]), and p

66 ssessments are limited as they require an in-person evaluation by a neurology subspecialist or specia

67 ns for osteomyelitis, 0.5 to 0.9 per 100 000 persons for central nervous system abscesses, and 24.4 t

68 h SUDs increased from 1.1 to 2.1 per 100 000 persons for IE, 1.4 to 2.4 per 100 000 persons for osteo

69 0 000 persons for IE, 1.4 to 2.4 per 100 000 persons for osteomyelitis, 0.5 to 0.9 per 100 000 person

70 stem abscesses, and 24.4 to 32.9 per 100 000 persons for skin and soft tissue infections.

71 the urine metabolome in identifying at-risk persons for T2D and suggest urine 3-hydroxyundecanoyl-ca

72 of the disadvantages associated with the in-person format and demonstrated the advantages of moving

73 age; some must undertake strategies to reach persons >=15 years of age and close immunity gaps.

74 -PCV, but no significant changes occurred in persons >=5 years of age.

75 5% of adults in the United States-37 million persons-have chronic kidney disease (CKD).

76 ed with a 92.2% seropositive rate among 1057 persons hired at age >50 years, only 84.4% of approximat

77 of visual processing, face shape similarity, person identity, and social relationships.

78 The APPS may be operated by a single person in the operating room suite within intraoperative

79 ntion condition (simultaneously with another person in the same room) while EEG signals were measured

80 p examinations, dementia was diagnosed in 61 persons in 1998 and additional 47 persons in 2005 to 200

81 osed in 61 persons in 1998 and additional 47 persons in 2005 to 2008.

82 among human immunodeficiency virus-infected persons in Africa.

83 andomized trial of 19,114 community-dwelling persons in Australia and the United States >=65 years of

84 The median age of persons in the risk interval was 57.5 years (range, 24 t

85 We included 292,000 persons in the Skane population and 1,419 from the MOA s

86 ided safety-net care to more than 27 million persons, including 573 026 prenatal patients, at approxi

87 Diagnostic testing to identify persons infected with severe acute respiratory syndrome-

88 However, it seems that an in-person interaction is still preferred when possible for

89 interindividually) and longitudinally within person (intraindividually).

90 otal DA concentration in the blood of normal person is generally determined to be ca. 0.5 to 6.2 ng/m

91 uidelines suggest to discontinue PrEP when a person is no longer at risk for HIV, but effectively imp

92 n, at least in part, why every HSV1-infected person is not equally likely to develop HSV1-associated

93 The decontamination of exposed persons is a priority following the release of toxic che

94 n RT, 9 nonpolymorphic TSMs occurred in >=10 persons: K40R, A62V, K70R, Y115F, Q151M, M184VI, S215Y.

95 confirmed infection, approximately one in 16 persons lacked IgG antibodies.

96 calculated: second highest FRI score at the person level (the maximum FRI score for each tooth was d

97 ing and positive affect and mood on a within-person level.

98 me contingencies, above and beyond fostering person-level dispositions such as self-esteem.

99 Test positivity was greater for persons living in zip codes with lower annual household

100 ing rates, and associated risk factors among persons living with HIV (PLWH), including by anatomic si

101 tic or pre-symptomatic, and that an infected person may infect 5.6 other individuals on average.

102 for up to 6 years (median three samples per person, median time from first to last sample, 4.3 years

103 Among infants, incidence per 1,000 person-months was 15.4 (95% CI, 12.5-18.8); incidence di

104 The identification of healthy persons more susceptible to dry eye (DED) symptoms devel

105 creening for bacterial vaginosis in pregnant persons not at increased risk for preterm delivery.

106 e, we use population-based data from ~22,000 persons of known HIV status to characterize migratory pa

107 Among persons older than 55 years, the ICER for F/TAF remained

108 actice guideline for the care of transgender persons on the basis of the best available evidence from

109 ormed consent, or protections for vulnerable persons or communities.

110 and 9.89 (95% CI 8.7-11.1) among DAA-treated persons (P < .001).

111 tionships that we observe is integral during person perception, to better help us interact in differi

112 es than objects by age 5, responses to first-person perspective motion were not yet detectable at thi

113 the 3rd-) person perspective, p < 0.001.

114 portion seronegative ranged from 0% among 79 persons previously hospitalized to 11.0% among 308 perso

115 ued protective measures and for vaccines for persons previously infected with SARS-CoV-2.

116 ive samples, we find that person-country and person-region value congruence predict six well-being me

117 This model tested whether each person's depression and stress predicted their own decis

118 ore cognitive domains that interferes with a person's independence in daily activities.

119 tand the source of these associations with a person's place of residence.

120 Horizontal exposures to persons shedding virus in bodily secretions (young child

121 e collective doses being 885 000 and 755 000 person-sievert, respectively.

122 ay help guard against negative effects of in-person social deprivation and other pandemic-related str

123 ific CD4 T cells in a cohort of HIV-infected persons starting antiretroviral treatment (ART) in a hig

124 g used to rule out infection among high-risk persons, such as exposed inpatients and health care work

125 sons who are HIV positive and taking ART and persons taking PrEP to prevent HIV infection are donatin

126 Among 3,302 persons tested for SARS-CoV-2 by BinaxNOW TM and RT-PCR

127 irectly upon presentation; an additional 882 persons tested positive in an ambulatory setting before

128 In a healthy person, the kidney filters nearly 200 g of glucose per d

129 n those impacted by exploitation: trafficked persons, their families, and the population at large.

130 eeded to treat/enroll (NNT) for 1 additional person to achieve viral suppression was calculated.

131 w estimation of rate ratios or to allow each person to serve as his/her own control (as we see with c

132 % of gross domestic product [GDP]; $5259 per person) to an estimated $3.1 trillion in 2016 (17.9% of

133 Rapid person-to-person transfer of viruses such as SARS-CoV-2

134 avirus pulmonary syndrome and to reconstruct person-to-person transmission events.

135 very country in the world with extraordinary person-to-person transmission.

136 roviders demonstrated a preference for an in-person training workshop, though further investigation i

137 Rapid person-to-person transfer of viruses such as SARS-CoV-2 and their

138 monary syndrome and to reconstruct person-to-person transmission events.

139 ry in the world with extraordinary person-to-person transmission.

140 (CONSORT) 2010 guideline, CONSORT for within-person trial (WPT) extension, and a new 3-item checklist

141 the second is one less uncontrolled off-the-person type database known as CYBHi.

142 entially important facial signals and within-person variability in expressions.

143 Interestingly, preference for in-person versus virtual surgical consultation reflected ac

144 re provided with ID consultations, either in person, via teleID, or both.

145 e can increase 7-day follow-up and reduce in-person visits with comparable 30-day clinical outcomes w

146 emedicine as an acceptable substitute for in-person visits, especially during the pandemic.

147 , minimize travel, and reduce unnecessary in-person visits.

148 Knowing when a person was infected with Mycobacterium tuberculosis (M.t

149 he possibility that any nonspeaking autistic person who communicates with assistance could be conveyi

150 be considered a successful outcome: first, a person who initiates PrEP must not seroconvert; second,

151 For persons who are exposed, the standard of care is observa

152 s of the GFR distribution are lower in older persons who are healthy than in middle-aged persons who

153 persons who are healthy than in middle-aged persons who are healthy.

154 Persons who are HIV positive and taking ART and persons

155 ed TET enzymatic activities in the brains of persons who died with AD suggest that this reduction is

156 Among 12 persons who infected mosquitoes, polymerase chain reacti

157 Persons who inject drugs (PWID) are at risk of invasive

158 s in healthcare access and utilization among persons who inject drugs (PWID) by state Medicaid expans

159 among persons with IDU and at least 100 000 persons who inject drugs (PWID) with skin and soft-tissu

160 mmunodeficiency virus (HIV) infections among persons who inject drugs (PWID).

161 ment and reduction in HIV transmission among persons who inject drugs (PWID).

162 Persons who rapidly died of severe COVID-19 illness may

163 It has been suspected that infected persons who remain asymptomatic play a significant role

164 We assume that persons who shift from passive modes of transport (e.g.

165 onfirmed incident SARS-CoV-2 infection among persons who were SARS-CoV-2 negative at enrollment.

166 lighted priorities to consider for any young person with sickle cell disease transitioning from paedi

167 d from 0.6% for a urogenital condition among persons with a developmental disorder to 54.1% for a cir

168 viors such as smoking cessation or in aiding persons with a family history of HNC to evaluate their r

169 f footwear type on stability and mobility in persons with a history of falls, and (2) determine wheth

170 nsure that rabies PEP is administered to all persons with a suspected rabies exposure, while avoiding

171 16 genes with consistent differences between persons with AD and controls.

172 ety of sodium phenylbutyrate-taurursodiol in persons with ALS.

173 ety of a combination of the two compounds in persons with amyotrophic lateral sclerosis (ALS) are not

174 We compared survival among persons with and without TB at enrollment in HIV care, s

175 Some 500 million persons with any of these mutations are mostly asymptoma

176 spoken language comprehension therapies for persons with aphasia remains equivocal.

177 s previously hospitalized to 11.0% among 308 persons with asymptomatic infections.

178 Persons with chronic, untreated HCV infections (aIRR 1.4

179 on (80.7%) originated from prescriptions for persons with commercial insurance, $200 million (9.6%) f

180 s may partly explain why smokers and elderly persons with compromised surfactant function are at incr

181 Our study comprised 8,345 persons with hepatic steatosis (fatty liver index >60) w

182 rvations of gut microbiota alterations among persons with HIV (PWH).

183 oss leading to increased fracture rate among persons with HIV (PWH).

184 Persons with HIV had greater risk of ARR than persons wi

185 l medical care and achieve desired outcomes, persons with HIV must be consistently engaged in care an

186 sive anal squamous-cell carcinoma (IASCC) in persons with HIV-1, we performed a single-center, retros

187 nts, 22.6% of women ages 18-24, and 34.1% of persons with HIV.

188 ninvasive predictors of clinical outcomes in persons with HIV/HCV coinfection.

189 Persons with human immunodeficiency virus (PWH) with per

190 r 9 (45%) of 20 highly treatment-experienced persons with human immunodeficiency virus, extensive ant

191 timates of thousands of episodes of IE among persons with IDU and at least 100 000 persons who inject

192 Treatment benefits are more pronounced in persons with more advanced liver fibrosis.

193 revent falls in PD.SIGNIFICANCE STATEMENT In persons with Parkinson's disease, gait dysfunction and t

194 Severe disease centers on older persons with preexisting conditions and not infants or i

195 All scoring systems were more accurate in persons with risk factors for NAFLD at baseline, with AU

196 ds for IE and other serious infections among persons with substance use disorders (SUDs) are unknown.

197 hospitalization for serious infections among persons with SUDs are increasing, driven primarily by yo

198 In persons with the protective genetic alleles of complemen

199 QALYs and a $14 100 lower lifetime cost per person, with an ICER of $34 300/QALY, compared to no int

200 ded 6,778 survivors of AYA cancer and 87,737 persons without a history of cancer.

201 , 36 with alcohol use disorder (AUD), and 17 persons without AUD (controls).

202 Older persons without dementia at study enrollment (n = 1,010)

203 ersons with HIV had greater risk of ARR than persons without HIV (adjRR, 9.6; 95% CI, 6.9-13.3), and

204 Compared to persons without IE, patients with a history of IE had a

205 2019 (Covid-19), have spread to millions of persons worldwide.

206 If only 30% of tested persons would wait for results, the prevalence reduction

207 d drug-free remission (incidence rate = 0.28/person-year [PY], 95% confidence interval [CI] 0.22-0.35

208 7), and 6.2 (95% CI, 5.4-7.2) deaths per 100 person-year among patients treated with DAA, IFN, and an

209 BV (Nugent 7-10) incidence was 10.18 per person-year at risk in the control group, and lower in t

210 group, and lower in the metronidazole (1.41/person-year; p = 0.004), Ecologic Femi+ (3.58/person-yea

211 erson-year; p = 0.004), Ecologic Femi+ (3.58/person-year; p = 0.043), and Gynophilus LP groups (5.36/

212 ; p = 0.043), and Gynophilus LP groups (5.36/person-year; p = 0.220).

213 SD/person/year), onsite sanitation (2-14 USD/person/year), and mini-sewers connecting several toilets

214 h (total financial requirements of 16-24 USD/person/year), followed by container-based sanitation (10

215 wed by container-based sanitation (10-17 USD/person/year), onsite sanitation (2-14 USD/person/year),

216 al toilets to communal septic tanks (3-5 USD/person/year).

217 voiding 1.75 million deaths or 20.5 trillion person years of life lost would be valued at $10.2 to $1

218 ior, HCV incidence would drop to 0.6 per 100 person-years (76% decline).

219 ipants who had initiated ART was 1.9 per 100 person-years (95% CI 0.9-3.9).

220 nterval [CI], 1754-1789) and 303 per 100 000 person-years (95% CI, 295-310), respectively, between 20

221 severe sepsis in adults was 1772 per 100 000 person-years (95% confidence interval [CI], 1754-1789) a

222 HZ incidence rate was 9.92/1000 person-years (95% confidence interval [CI], 9.82-10.01).

223 nce rate of 0.74 cases per 1000 HIV-infected person-years (95% confidence interval, 0.43-1.05).

224 verall, the mortality rate was 5.8 per 1,000 person-years (or 831 deaths per 100,000 live births) in

225 uctive disease (by CAC scores: 6.2 per 1,000 person-years (PY) for CAC = 0 to 42.3 per 1,000 PY for C

226 (observed January 2010-December 2016; total person-years 6,498,607) with linked FHS utilization and

227 re revealed by CTA in 103 patients (17.2/100 person-years [95% CI, 13.9-20.5]).

228 LNJSA has higher incidence (13 vs 8/100 000 person-years [PY]), occurs in older, more comorbid patie

229 nce increased from 0.0 (95% CI, 0.0-2.9)/100 person-years after ART in Fiebig I to 15.9 (7.6-29.2) in

230 standardized CVD mortality rate was 2.7/1000 person-years among both men and women with HIV.

231 varian cancer incidence was 61 cases/100 000 person-years among ever users and 55 cases/100 000 perso

232 -years among ever users and 55 cases/100 000 person-years among never users (estimated risk differenc

233 3 379 events, with 66.3 and 70.4 events/1000 person-years among statin users and nonusers, respective

234 d incidence in Kathmandu was 484 per 100 000 person-years and in Kavrepalanchok was 615 per 100 000 p

235 diovascular events from 1.37 to 6.55 per 100 person-years at 2 years (adjusted hazard ratio, 4.8 [95%

236 dian of 11.2 years of follow-up (3.8 million person-years at risk), 2168 women developed ovarian canc

237 n-years for 70 to <100 mg/dl, and 94.0/1,000 person-years for >=100 mg/dl.

238 rs for the LDL-C <70 mg/dl group, 60.3/1,000 person-years for 70 to <100 mg/dl, and 94.0/1,000 person

239 tes of cardiovascular events were 55.2/1,000 person-years for the LDL-C <70 mg/dl group, 60.3/1,000 p

240 age-standardized ASCVD event rate per 1,000 person-years for those with a history of 1, 2, and 3 con

241 phageal cancer and 0.09 ONJ events per 1,000 person-years in the alendronate cohort and 6.62, 7.36, 0

242 us cardiovascular events, with rates per 100 person-years in the placebo, 50 mg, 150 mg, and 300 mg c

243 The age-adjusted incidence per 1000 person-years increased with the number of SDH for both f

244 88 818 SPC deaths occurred during 11 197 890 person-years of follow-up (mean, 7.3 years).

245 ractice Research Datalink, with 66.2 million person-years of follow-up from 2002 to 2017.

246 During 94,311 person-years of follow-up in 2007-2017, 7,779 primary ev

247 The corresponding incidence rates per 10 000 person-years of follow-up in the highest vs the lowest q

248 After 440 person-years of follow-up, 44% of YBMSM initiated PrEP t

249 In 47.5 million person-years of follow-up, 49,955 (2.3%) women were diag

250 During 5,291,518 person-years of follow-up, we documented 15,837 incident

251 o are waitlisted in a center relative to the person-years referred for evaluation to a program.

252 th newer rather than injectable DMTs for 3.7 person-years to prevent 1 relapse.

253 plasia) at baseline, incidence rates per 100 person-years were 1.09 (95% CI, 0.85-1.33) for low-grade

254 Diabetes incidence rates per 1000 person-years were 20.6 (95% confidence interval [CI] 19.

255 ng pregnancy was 42.9 (95% CI 32.4-57.0/1000 person-years) among women for whom the mesenteric defect

256 erval, 3.09-7.27] vs 0.87 [.42-1.83] per 100 person-years) and dyslipidemia (8.16 [5.42-12.27] vs 3.9

257 c control (incidence of 1 infection per 1000 person-years) by 2030.

258 y procedure, and 53.2 (95% CI 38.9-72.8/1000 person-years) for women in whom they had been left open.

259 The rate of the primary outcome (per 100 person-years) increased with HF duration: 10.2 (95% CI,

260 .16 [5.42-12.27] vs 3.99 [2.67-5.95] per 100 person-years) than those without NAFLD.

261 HIV rates diagnosis (per 100 000 person-years) were higher for women after syphilis (177.

262 sease in the comparison group (10 per 10 000 person-years), adjusted results showed no evidence of an

263 t, 639 patients died from CRC (0.55 per 1000 person-years), compared with 4451 reference individuals

264 n developed ovarian cancer (58 cases/100 000 person-years).

265 s were followed up over 7936 eye-years (4676 person-years).

266 ll sites (incidence rate 24.9 cases per 1000 person-years).

267 nd nonusers, respectively (weighted IRD/1000 person-years, -4.1 [95% CI, -5.1 to -3.0]).

268 (64.0 exposed vs. 96.2 unexposed per 100,000 person-years, P < 0.001).

269 871.1 [95% CI: 852.3, 890.6] cases per 1,000 person-years, respectively) and peaked in July each year

270 , 7.36, 0.69, 0.22 and 0.06 events per 1,000 person-years, respectively, in the raloxifene cohort.

271 , with an incidence of 2.95 and 2.88 per 100 person-years, respectively.

272 TAVR was 2.59, 0.71, and 0.40 events per 100 person-years, respectively.

273 d treatment (1951, 290, and 31 cases/100 000 person-years, respectively; P < .001).

274 idence, 190.4 (95% CI: 114.8-315.8) per 1000 person-years, than nonoverweight recipients, 56.1 (95% C

275 CI 9.03-11.60) additional deaths per 10 000 person-years.

276 r a median period of 7.8 y, totaling 282,855 person-years.

277 dence of RSV pneumonia was 29 cases per 1000 person-years.

278 en, 60% African American) contributed 30 007 person-years.

279 occurred: 2.3 (95% CI 0.3 to 16.6) per 1000 person-years.

280 ogic, 11 clinical) at a rate of 3.78 per 100 person-years.

281 rs and in Kavrepalanchok was 615 per 100 000 person-years.

282 D), with a mean incidence of 0.9-1.4 per 100 person-years.

283 s died, corresponding to 22 deaths per 1,000 person-years.

284 6.8% and an incidence of 0.58-2.89 per 1,000 person-years.

285 graphic subgroups (e.g., CVD rates per 1,000 person-years: age 18 to 24 years, 0.64; age 25 to 30 yea

286 o 5.85; rate difference, 56.4 cases per 1000 person-years; 95% CI, 38.0 to 66.8; P<.001), but the FEV

287 h celiac disease (9.7 vs 8.6 deaths per 1000 person-years; absolute difference, 1.2 per 1000 person-y

288 ed AF (incidence rate 136.4 vs 21.6 per 1000 person-years; absolute RD at 5 years, 39.3%; 95% CI, 33.

289 ve AF (incidence rate, 42.5 vs 25.0 per 1000 person-years; absolute RD at 5 years, 6.2%; 95% CI, 2.2%

290 eath (incidence rate, 133.2 vs 86.8 per 1000 person-years; absolute RD at 5 years, 9.4%; 95% CI, 4.9%

291 etectable CAC (20.1 vs. 5.0 events per 1,000 person-years; adjusted hazard ratio [HR]: 2.35; 95% conf

292 d detectable hs-cTnT (15.4 vs. 5.2 per 1,000 person-years; adjusted HR: 1.47; 95% CI: 1.21 to 1.77; p

293 son-years; absolute difference, 1.2 per 1000 person-years; hazard ratio [HR], 1.21 [95% CI, 1.17-1.25

294 group (incidence, 2.5 vs. 3.6 events per 100 person-years; hazard ratio, 0.69; 95% confidence interva

295 th 4451 reference individuals (0.38 per 1000 person-years; HR 1.59, 95% CI 1.46-1.72) during the same

296 oke (incidence rate, 5.6 versus 3.2 per 1000 person-years; HR, 1.19 [95% CI, 0.82-1.72]).

297 ion (incidence rate, 3.9 versus 1.8 per 1000 person-years; HR, 1.37 [95% CI, 0.88-2.13]) and ischemic

298 range of 18 to 39 years (1.9 vs 1.1 per 1000 person-years; HR, 1.69 [95% CI, 1.47-1.94]; P values for

299 ighest quartile (80.6 vs 24.2 cases per 1000 person-years; RR, 3.33; 95% CI, 1.89 to 5.85; rate diffe

300 incidence and mortality are increasing among persons younger than 50 years old in the United States,